In addition to targeting GSCs, G47-mIL12 also increases IFN-γ release, inhibits angiogenesis, and decreases the number of regulatory T cells in the tumor, indicating that G47Δ-mIL12 offers a comprehensive strategy for targeting the immune system, the tumor microenvironment, and GSCs, with potential therapeutic benefits in a rigorous GBM model [115]. The gene discussed is IFNG; the disease is neoplasm.